Skip to main content
Premium Trial:

Request an Annual Quote

FDA to use Ingenuity Pathways Analysis for Review of Pharmacogenomics Data

NEW YORK, June 21 (GenomeWeb News) - Ingenuity said today that the US Food and Drug Administration has licensed its Ingenuity Pathways Analysis platform for use in the review of pharmacogenomics data submissions. 

 

The FDA and Ingenuity will collaborate on merging Ingenuity's data and software suite with the FDA's ArrayTrack informatics system using a new integration module in Ingenuity Pathways Analysis.

 

ArrayTrack, a microarray data-management and -analysis system, was developed by the FDA's Center for Toxicoinformatics at the NationalCenter for Toxicological Research (NCTR). Further details of the system are available here.

 

Last August, the FDA integrated another pathway database, PathArt from Jubilant Biosys, into ArrayTrack.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.